The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on quality of life (QoL) in relapsed/refractory multiple myeloma (RRMM)? 

Mohty discussed the impact of elranatamab on QoL in patients with RRMM, highlighting its benefits in symptom relief, mobility, and overall well-being. Mohty also addressed the associated risk of cytokine release syndrome (CRS), neurotoxicity, and infections, concluding with the latest clinical trial data and emphasizing the need for ongoing research to optimize the role of elranatamab and other bispecific antibodies in patient care.  

Key learnings

• Overall, elranatamab has positively impacted QoL in many patients with RRMM by providing rapid symptom relief, reducing bone pain and fatigue, improving mobility, and decreasing healthcare visits. 
• Better disease control also contributes to improved psychological well-being. 
• These benefits ultimately enhance daily functioning and overall well-being, allowing patients to resume their daily activities. 
• Adverse events are a concern; however, the implementation of step-up dosing helps to reduce the risks of severe CRS and neurotoxicities. 
• The risk of infections remains significant. However, mitigation strategies such as prophylactic antivirals, antifungals, and intravenous immunoglobulin administration can help preserve QoL. 
• Clinical trial data from the MagnetisMM-3 (NCT04649359) trial support these findings, demonstrating improved patient-reported outcomes in global health status, functional ability, and symptom management. 
• Ongoing trials aim to further clarify the role of elranatamab and other bispecific antibodies in enhancing QoL. 

This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.